Evidence map›Paper›PMID 36370359›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Using the Bleomycin-Induced Model of Fibrosis to Study the Contribution of CCN Proteins to Scleroderma Fibrosis.

Alexander Peidl, John Nguyen, Pratyusha Chitturi, Bruce L Riser, Andrew Leask

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Alexander PeidlDepartment of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada.
John NguyenCollege of Dentistry, University of Saskatchewan, Saskatoon, SK, Canada.
Pratyusha ChitturiCollege of Dentistry, University of Saskatchewan, Saskatoon, SK, Canada.
Bruce L RiserBLR Bio LLC, Kenosha, WI, USA.
Andrew LeaskCollege of Dentistry, University of Saskatchewan, Saskatoon, SK, Canada. anl312@usask.ca.
University of Saskatchewan · CARosalind Franklin University of Medicine and Science · USWestern University · CA

Funding

CIHR
6 · The paper itself

Abstract

Approximately 45% of the deaths in the developed world result from conditions with a fibrotic component. Although no specific, focused anti-fibrotic therapies have been approved for clinical use, a long-standing concept is that targeting CCN proteins may be useful to treat fibrosis. Herein, we summarize current data supporting the concept that targeting CCN2 may be a viable anti-fibrotic approach to treat scleroderma. Testing this hypothesis has been made possible by using a mouse model of inflammation-driven skin and lung fibrosis.

Indexed as

Pulmonary FibrosisScleroderma, SystemicAnimalsBleomycinConnective Tissue Growth FactorDisease Models, AnimalFibrosisSkinBleomycinConnective Tissue Growth FactorBleomycinCCN2CCN proteinsCTGFFibrosisLung fibrosisMatricellular proteinsScleroderma

Identifiers

PMID36370359
OpenAlexW4309048714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.